Best Practice & Research Clinical Haematology
Volume 23, Issue 1 , Pages 145-153 , March 2010

Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches

  • Vicki A. Morrison, MD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 612 467 4135; fax: +1 612 727 5673.

References 

  1. Wadhwa P, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33:240–249
  2. Ravandi F, O'Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother. 2006;55:197–209
  3. Aittoniemi J, Miettinen A, Laine S, et al. Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia. Leuk Lymphoma. 1999;34:381–385
  4. Morrison VA, Hibbs JR, Janoff EN. Systemic and mucosal immunoglobulin levels and risk of infection in patients with chronic lymphocytic leukemia and multiple myeloma. Blood. 1996;88(Suppl. 1):240a;(Abstract #948)
  5. Sinisalo M, Aittoniemi J, Koski T, et al. Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status. Leuk Lymphoma. 2004;45:2451–2454
  6. Francis S, Karanth M, Pratt G, et al. The status on immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer. 2006;107:1023–1033
  7. Rai KR, Peterson B, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750–1757
  8. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993;2:1695–1700
  9. Keating MJ, O'Brien S, Kantarjian H, et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993;81:2878–2884
  10. Keating MJ, O'Brien SO, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165–1171
  11. Anaissie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med. 1992;117:466–469
  12. Morrison VA, Rai KR, Peterson B, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup study cancer and leukemia group B 9011. J Clin Oncol. 2001;19:3611–3621
  13. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998;129:559–566
  14. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999;5:444–447
  15. Morra E, Nosari A, Montillo M. Infectious complications in chronic lymphocytic leukemia. Hematol Cell Ther. 1999;41:145–151
  16. Hensel M, Kornaker M, Yammeni S, et al. Disease activity and pretreatment, rather than hypogammaglobulinemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukemia. Br J Haematol. 2003;122:600–606
  17. Molteni A, Nosari A, Montillo M, et al. Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes. Haematol. 2005;90:1145–1147
  18. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319–2325
  19. Steurer M, Pall G, Richards S, et al. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat Rev. 2006;32:377–389
  20. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71–75
  21. Flinn IW, Neuberg D, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25:793–798
  22. Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an effective treatment for advanced chronic lymphocytic leukemia (CLL): Results of a phase II study of the German CLL Study Group. Br J Haematol. 2001;114:342–348
  23. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885–891
  24. Eichhorst BF, Busch R, Schweighofer C, et al. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol. 2006;136:63–72
  25. O'Brien S, Moore JO, Boyd TE, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2007;25:1114–1120
  26. Kowal M, Dmoszynska A, Lewandowski K, et al. Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)–polish multicentre study. Leuk Lymphoma. 2004;45:1159–1165
  27. Jindra P, Koza V, Boudova L, et al. Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation. Bone Marrow Transpl. 2003;31:951–952
  28. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the minnie pearl cancer research network. J Clin Oncol. 2003;21:1746–1751
  29. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and leukemia group B 9712 (CALGB 9712). Blood. 2003;101:6–14
  30. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079–4088
  31. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070–4078
  32. Robak T, Blonski JZ, Urbanska-Rys H, Blasinska-Morawiec M, Skotnicki AB. 2-chlorodeoxyadenosine (cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia. 1999;13:518–523
  33. Robak T, Blasinska-Morawiec M, Blonski JZ, Dmoszynska A. 2-chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 1999;34:151–157
  34. Byrd JC, Peterson B, Piro L, et al. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB study 9211. Leukemia. 2003;17:323–327
  35. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood. 1988;72:1069–1073
  36. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients. Br J Haematol. 2000;108:357–368
  37. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood. 2000;96:2723–2729
  38. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: A phase II trial of Cancer and Leukemia Group B. J Clin Oncol. 1989;7:433–438
  39. Oken MM, Lee S, Kay NE, et al. Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma. 2004;45:79–84
  40. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006;24:1575–1581
  41. Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007;109:2291–2298
  42. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia. 2004;18:484–490
  43. Lundin J, Osterborg A. Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia. Semin Hematol. 2004;41:234–245
  44. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278–3281
  45. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–3561
  46. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891–3897
  47. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768–773
  48. Cortelezzi A, Pasquini MC, Sarina B, et al. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with chemotherapy-refractory chronic lymphocytic leukemia. Haematol. 2005;90:410–412
  49. Martin SI, Marty FM, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43:16–24
  50. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616–5623
  51. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003;101:3413–3415
  52. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: Results of a phase II trial. J Clin Oncol. 2005;23:7024–7031
  53. O'Brien S, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma. 2006;7:125–130
  54. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual diseased after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003;98:2657–2663
  55. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004;18:1093–1101
  56. Rai KR, Byrd JC, Peterson BL, Larson RA. A phase II trial of fludarabine followed by alemtuzumab in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: cancer and leukemia Group B (CALGB) study 19901. Blood. 2002;100:205a–206a
  57. Rai KR, Byrd JC, Peterson BL, et al. Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 19901. Blood. 2003;102:676
  58. Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica. 2002;87:695–700
  59. Morrison VA, Peterson BL, Rai KR, et al. Alemtuzumab increases serious infections in patients with previously untreated chronic lymphocytic leukemia (CLL) receiving fludarabine-based therapy: A comparative analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901). Blood. 2007;110:233
  60. Lin T, Donohue KA, Lucas MS, et al. Consolidation therapy with subcutaneous (SC) alemtuzumab results in serious infectious toxicity in previously untreated CLL patients who achieve a complete remission (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101. Blood. 2007;110:232–233
  61. Shvidel L, Shtalrid M, Bairey O, et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44:1947–1950
  62. Morrison VA, Byrd JC, Peterson BL, et al. Adding rituximab to fludarabine therapy for patients with untreated chronic lymphocytic leukemia (CLL) does not increase the risk of infection: cancer and leukemia group B (CALGB) study. Blood. 2003;102:440a
  63. Laurenti L, Piccioni P, Cattani P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematol. 2004;89:1248–1252
  64. Smith TF, Espy MJ, Mandrekar J, et al. Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. Clin Infect Dis. 2007;45:1056–1061
  65. O'Brien S, Ravandi-Kashani F, Wierda WG, et al. A randomized trial of valacyclovir versus valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab. Blood. 2005;106:830a
  66. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia . Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med. 1988;319:902–907
  67. Molica S, Musto P, Chiurazzu F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. results of a crossover study. Haematologica. 1996;81:121–126
  68. Sinisalo M, Aittoniemi J, Kayhty H, et al. Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44:649–652
  69. Hartkamp A, Mulder AH, Rijkers GT, et al. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine. 2001;19:1671–1677
  70. Sinisalo M, Aittoniemi J, Oivanen P, et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol. 2001;114:107–110

PII: S1521-6926(09)00105-4

doi: 10.1016/j.beha.2009.12.004

Best Practice & Research Clinical Haematology
Volume 23, Issue 1 , Pages 145-153 , March 2010

Article Tools